Christopher Anzalone Salary and Compensation - ARROWHEAD PHARMACEUTICALS, INC. CEO Pay 2025

In fiscal year 2025, Christopher Anzalone, President and Chief Executive Officer of ARROWHEAD PHARMACEUTICALS, INC. (ARWR), received total compensation of $9.0 million.

Christopher Anzalone's compensation breakdown includes: base salary of $981K, stock awards valued at $6.8 million, non-equity incentive compensation of $1.2 million, and other compensation of $3K.

Compared to fiscal year 2024, Christopher Anzalone's total compensation decreased 27% from $12.4 million to $9.0 million.

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Executive Pay 2025

ARROWHEAD PHARMACEUTICALS, INC.'s top 6 named executive officers received combined total compensation of $19.5 million in fiscal year 2025.

The named executive officers disclosed in ARROWHEAD PHARMACEUTICALS, INC.'s 2025 proxy statement are:Christopher Anzalone (President and Chief Executive Officer) with total compensation of $9.0 million, Patrick O’Brien (Chief Operating Officer) with total compensation of $3.0 million, James Hamilton (Chief Medical Officer) with total compensation of $3.0 million, Kenneth Myszkowski (Former Chief Financial Officer) with total compensation of $2.7 million, Daniel Apel () with total compensation of $1.8 million, and Tracie Oliver (Former Chief Commercial Officer) with total compensation of $43K.